To the best of our knowledge, this the first study conducted in a group of NSCLC patients under osimertinib therapy that combines the detection of EGFR mutations in plasma cfDNA and CTCs with the technology of crystal dPCR. Here, EGFR is linked to non-small cell lung carcinoma.